Why the Canada Generic Drug Market Is Growing With Rising Demand for Affordable Medicines

Around the world healthcare is struggling to keep up with cost concerns without sacrificing quality and Canada is facing this challenge. The growth of generic drugs has emerged as a cost-effective answer as they have all the same therapeutic benefits as the brand name medication, at a considerably lower price. The demand for affordable treatment continues to grow, so much so that the Canada generic drugs market has been steadily growing over the past few years.

According to IMARC Group, Canada generic drugs market reached USD 11.2 Billion in 2025, and it is expected to grow to reach USD 20.4 Billion by 2034 growing at a CAGR of 6.73% during 2026-2034.

The market is booming due to factors such as increase in number of chronic diseases such as cardiovascular diseases, diabetes, arthritis, etc., these conditions have resulted in need for a number of medications, for long periods of time. Thus a considerable burden is put on both patient and the healthcare system of country. Hence the availability of generic drugs have proved to be beneficial for a considerable section of the population.

The expiration of patent life of branded drugs is another main factor that is contributing to market growth, with companies now free to produce generic versions of the drugs that are known to work just as effectively at a lower price.

Canadian government support has also played a significant role in expanding the generic drug market. With a range of initiatives from the government's own initiatives and awareness campaigns, along with incentives for prescribing generics, these drugs are becoming increasingly attractive. The market is seeing a growth with the latest announcement from Canada approving generic versions of sophisticated drugs such as semaglutide that are used to treat diabetes, which is reducing the prices of a previously highly expensive drug.

The patients themselves are more aware about the benefits of generic drugs compared to earlier; this has led to increased demand across various classes of people. As generic drugs are required to follow stringent safety and efficacy tests similar to brand name drugs, more and more people are gaining confidence in their use.

Healthcare Infrastructure across the nation has been expanding continuously; and has provided more reach to people for accessibility to medical services and treatment options. Hence resulting in increased requirement of medications for the entire populace. Accessibility of generic drugs through offline and online drug stores and distribution channels further aided in growth.

In terms of segmentation of the Canadian generic drugs market, in terms of dosage forms it is available in oral, topical, injectable and inhalation formulations. Furthermore it has a wide application across numerous therapeutic areas including central nervous system disorders, cardiovascular diseases, diabetes, oncology, respiratory conditions etc.

The Canadian generic drugs market has a dynamic competitive landscape. Key market players in the region include; Apotex Inc., Sandoz AG, Teva Pharmaceutical Industries, Sun Pharma and Pharmascience Inc., and they have further developed product portfolio and distribution networks.

The Canadian generic drugs market is quite interesting because it aligns well with government initiatives towards cost control and accessibility of drugs across the nation.

With the continuous patent expiration of drugs and various government support and policies to increase the usage of generic drugs, it is likely to grow in the near future with also the burden of chronic diseases in the Canadian population increasing. Availability of medications has been and continues to be a critical factor when determining how people access treatments, so generic drugs will remain a vital part of the Canadian pharmaceutical system.

For deeper insights into market forecasts, therapeutic segments, and competitive landscape, explore the full IMARC Group report.